ArticleFrontiers in aging2025
Reversal of perturbed DNA damage response and HIV latency by a histone methyltransferase inhibitor in virally suppressed individuals living with HIV.
Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxidative stress contributes to DNA damage, further leading to cellular senescence. HIV infection increases oxidative stress and interferes in DNA damage response. Hence, a study was conducted to assess the extent of DNA damage by evaluating global methylation, 8-hydroxy-2'-deoxyguanosine (8-OHdG), and prelamin A levels in people living with HIV (PLHIV), representing alterations at the genetic, epigenetic, and structural levels. We also investigated the effect of methylation modulators on these markers and HIV latency reversal. Methods: Middle-aged virally suppressed PLHIV on long-term antiretroviral therapy (ART) and non-infected controls were enrolled for the study. The levels of 5-methylcytosine in blood and plasma 8-OHdG were assessed using commercially available colorimetric and ELISA kits, respectively. Reactive oxygen species (ROS) and prelamin A expression in T cells were assessed by flow cytometry. The levels of DNA damage markers were analyzed for their correlation with immunosenescent and inflammatory markers. Samples were treated with RG108 and chaetocin to assess their effect on these markers and HIV reactivation. HIV reactivation was assessed by the expression of intracellular P24 by flow cytometry and gag copies by real-time PCR. Results: PLHIV had significantly lower global DNA methylation levels and higher 8-OHdG and prelamin A levels than their age-matched HIV-uninfected controls. The ROS levels did not differ significantly among them. Global methylation and prelamin A levels correlated with immunosenescent T cells. The 8-OHdG levels correlated positively with angiotensin-II levels and negatively with proinflammatory cytokines. Treatment with chaetocin increased the global methylation levels and diminished prelamin A accumulation in CD4 Conclusion: PLHIV on ART had higher DNA damage-related markers despite having comparable ROS levels than their age-matched controls. The immunotherapeutic potential of chaetocin for reversing premature aging as well as HIV latency needs to be explored further.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.